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Abstract 
It has been hypothesized that amphipathic peptides might bind to membranes prior to activating their 
cognate receptors, but this has proven difficult to test. The peptide hormone PYY3-36 is believed to 
perform its appetite suppressing actions through binding to hypothalamic Y2 receptors. It has been 
proposed that PYY3-36 via its amphipathic !-helix binds to the plasma membrane prior to receptor 
docking. Here our aim was to study the implication of this hypothesis using new analogs of PYY3-36. 
We first studied membrane binding of PYY3-36. Next, we designed a series of PYY3-36 analogs to 
increase membrane-binding affinity by substituting the N-terminal segment with a de novo designed !-
helical, amphipathic sequence. These 2-helix variants of PYY3-36 were assembled by solid-phase peptide 
synthesis. Pharmacological studies demonstrated that even though the native peptide sequence was 
radically changed, highly active Y2 receptor agonists were generated. A potent analog, with a Kd of 4 nM 
for membranes, was structurally characterized by NMR in the membrane-bound state, which clearly 
showed that it formed the expected 2-helix. The topology of the peptide-micelle association was studied 
by paramagnetic relaxation enhancement using a spin-label, which confirmed that the hydrophobic 
residues bound to the membrane. Our studies further supports the hypothesis that PYY3-36 associates 
with the membrane, and indicate that this can be used in the design of novel molecules with high receptor 
binding potency. These observations are likely to be generally important for peptide hormones and 
biopharmaceutical drugs derived from them. This new 2-helix variant of PYY3-36 will be useful as a tool 
compound for studying peptide-membrane interactions. 
  
Introduction 
Neuropeptide Y (NPY), pancreatic polypeptide (PP) and peptide YY (PYY) belong to the NPY family of 
peptides. These peptide hormones are ligands of the so-called Y receptors (Y1, Y2, Y4, Y5),[1] that are 
involved in a variety of physiological functions, including central (CNS) and peripheral control of blood 
pressure, heart rate, food intake, gut motility, gastric, and gut secretions.[2-3] Recent data have indicated 
a role for peripherally circulating PYY3-36 in appetite regulation, presumably via interaction with 
hypothalamic Y2 receptors,[3-5] which has led to considerable efforts into developing novel PYY3-36 
peptide analogs for the treatment of obesity both by us[6-9] and others[10-14].  
PYY is co-secreted with the glucagon-like peptides 1 and 2 as well as oxyntomodulin from the 
endocrine L-cells lining the gut following the ingestion of a meal. Full-length PYY1-36 is a high-affinity 
Y1, Y2 and Y5 receptor ligand, but N-terminal truncation of PYY1-36 by dipeptidyl peptidase IV 
(DPP-IV)[15] generates PYY3-36 which is more selective for the Y2 (and Y5) receptors and believed to 
be the natural ligand of the Y2 receptor.[4-5] Although scientific efforts over the past three decades have 
greatly enhanced our understanding of the Y receptor pharmacology, there is still only a limited 
understanding of the molecular and biophysical mechanisms underlying the selectivity shifts of PYY and 
NPY towards the Y2 receptor upon N-terminal truncation. Kaiser and Kezdy, and then Schwyzer  have 
suggested that amphipathic peptides might bind to membranes before binding to their membrane-bound 
receptors and that the membrane binding induces a conformation in the peptides suitable for receptor 
binding (the membrane compartment model).[16-19] According to the membrane compartment model 
amphipathic peptides that bind to GPCRs are bifunctional, where one part of the peptide (the address) 
directs the peptide towards the membrane, while another part (the message) binds to and activates the 
receptor.[19]   
Recently, the membrane compartment model has been applied to study the NPY family of peptides and 
has shed new light on the peptide receptor binding mechanism. In peptides from the NPY family, the 
amphipathic !-helix was proposed to constitute the ‘address’, while the C-terminal pentapeptide would 
form direct contacts with the receptor.[20] Comparison of structures of PP, NPY and PYY in the absence 
and presence of a membrane model indicate that prior to receptor binding the ligand associates with the 
membrane.[20-22] This is based on NMR studies which have shown that full-length PYY1-36 in solution 
consists of a C-terminal receptor-recognizing pentapeptide that is attached to an amphipathic !-helix and 
followed by a N-terminal polyproline helix, and that hydrophobic contacts are formed between the !-helix 
and the N-terminal polyproline type.[21] Upon membrane association this hydrophobic contact is 
disrupted, and the hydrophobic face of the !-helix binds to the membrane surface and the N-terminal 
segment is released to freely diffuse in solution.[21] PYY3-36 truncated to PYY22-36 has very poor 
receptor binding,[13] which could indicate that the N-terminus either assists in binding to the receptor or 
binds to the membrane. 
Here, we first studied the membrane-binding properties of PYY3-36 using fluorescence and CD 
methods. Second, we designed potent Y2 receptor agonists with improved membrane surface binding. 
This was achieved by replacing the whole N-terminus of PYY with a de novo designed amphipathic 
!-helix (Figure 1), rather than by attaching a lipid which will insert into the membrane. The native !-helix 
was maintained as it likely plays a role in enabling binding of the C-terminal pentapeptide to the receptor. 
We speculated that the introduction of an additional amphipathic !-helix would provide peptides with a 
higher membrane affinity, due to an increased number of hydrophobic contacts with the outer leaflet of 
the membrane, which could result in an increased accumulation in the vicinity of the Y receptors. As the 
native N-terminus appears to be important for Y1 receptor affinity, we expected that this strategy could 
improve the Y2/Y1 receptor subtype selectivity. The peptides were assembled by solid-phase peptide 
synthesis, using a Fmoc protocol. Indeed, our work demonstrates that the additional amphipathic !-helix 
generally led to potent Y2 receptor agonists. In addition, sustained or improved selectivity for the Y2 
subtype was observed. Moreover, as intended by the novel design of the 2-helix PYY analogs, they 
associated with the membrane with much higher affinity. 
  
Methods 
Peptide synthesis 
The peptides were synthesized on Rink Amide TentaGel resin using the Fmoc/tBu strategy by automated 
solid-phase peptide synthesis on a Biotage/MultiSynTech SyroII or Syro WaveTM[23]. The N!-Fmoc-
protected amino acids (4 eq.) were coupled using HBTU (3.8 eq.) as coupling reagent, and HOBt (3.6 eq.) 
and HOAt (0.4 eq.) as additive, DIEA as base (7.8 eq.), in DMF. Coupling times were generally 2 " 2 h at 
room temperature or 2 " 10 min at 75 ºC by microwave-assisted SPPS[24]. N!-deprotection was 
performed using piperidine in DMF. The peptides were side-chain deprotected and simultaneously 
cleaved from the solid support by a TFA cocktail containing TES and H2O (95/3/2) as scavengers. 
Finally, the peptides were purified by RP-HPLC and characterized by analytical HPLC and mass 
spectrometry. The final products were obtained with >95% purity (for more detail see Supporting 
Information). 
 
Pharmacological assays  
Membrane fragments from BHK-21 and CHO cell lines expressing the human Y1 and Y2 receptor 
subtypes, respectively, and HEK293 cell line expressing either the human Y4 or Y5 receptor subtypes 
were used. 125I-PYY was used as radioligand for competition at the Y1, Y2 and Y5 receptors, and 125I-PP 
was used as radioligand for competition at the Y4 receptor. The signal transduction assay for the human 
Y1, Y2 and Y4 receptor subtypes utilizes HEK293 cells expressing a biosensor developed around a 
modified rat olfactory cyclic nucleotide gated (CNG) calcium channel engineered to be cAMP selective 
and thus function as a cAMP responsive biosensor that signals through calcium. In the human Y5 
receptor IPOne assay a HEK293 cell line stably expressing both the human Y5 receptor and the chimeric 
G-protein Gqi5 was used where Gqi5 ensures Gq signaling of the Gi coupled Y5 receptor. 
 
NMR 
For NMR structural studies a 1 mM solution of the peptide in 20 mM MES buffer, pH 5.5, in presence of 
300 mM d38-DPC (Cambridge Isotopes) was used. All spectra were recorded at 37 °C on a Bruker 700 
MHz Avance spectrometer equipped with a cryoprobe. For assignment purposes a 40 ms [1H,1H]-TOCSY 
and a 100 ms zero-quantum suppressed NOESY were measured and evaluated.[25] All spectra were 
assigned using the program XEASY.[26] Resonance assignments were largely following the sequential 
resonance assignment procedure.[27] Assignment was largely facilitated by knowledge of proton 
chemical shifts of PYY1-36, for which resonances of the C-terminal !-helix were characterized by very 
similar resonance frequencies. All proton frequencies were deposited in the BMRB database under 
accession code 17291. NOEs were converted into upper-distance restraints, and used in restrained MD 
calculations using the program DYANA.[28] Out of 100 computed structures the twenty lowest energy 
conformers were selected to represent the NMR ensemble. The latter was further refined in explicit water 
using the program AMBER.[29] RMSD calculations and preparation of figures was accomplished using 
the program MOLMOL.[30] For further information on statistics of restraints, energy of computed 
conformers, Ramachandran statistics etc. see the Supporting information. The coordinates are deposited 
in the pdb database under accession code 2I60. 
 
Membrane binding assay 
Brain lipid vesicles were formed by standard rehydration of Folch bovine brain extracts (fraction 1, 
Sigma-Aldrich), supplemented with 0.5 mol % 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(cap 
biotinyl) (DOPE-Biot.; Avanti Polar Lipids, Alabama, USA) and 0.5 mol % 3,3’-dioctadecyl-
oxacarbocyanine perchlorate (DiO) (Invitrogen, Denmark) for surface immobilization and visualization 
respectively, according to Bhatia et al.[31] Briefly, unilamellar vesicles were prepared by first drying 
down lipids to a thin film, then rehydrating in sorbitol (equimolar to experiment buffer) overnight at 37 
°C and finally the solution was subjected to 5 cycles of freeze/thaw and then extrusion (LipexTM 
Extruder, Northern Lipids, Burnaby, Canada,) through a poly-carbonate filter with a pore size of 0.8 #m 
(Millipore, Denmark).  
Cleaned glass surfaces were functionalized with BSA-biotin, passivated with BSA and activated with 
Streptavidin in order to tether the brain lipid vesicles through biotin-streptavidin coupling as previously 
described.[31] Binding of peptide to tethered vesicles was performed in TBS (10 mM TRIS, 95 mM 
NaCl, pH 7.4). All micrographs were acquired on a Leica TCS SP5 Confocal Fluorescence Microscope, 
with an AOBS/AOTF system allowing tuneable wavelength detection intervals. The objective used was 
an oil immersion HCX PL APO with x100 magnification (NA 1.4). Vesicle fluorescence intensity were 
detected at 495–600 nm (exc. at 488 nm) while peptide-Atto655 (peptide 20 and 21) fluorescence was 
detected at 640-780 nm (exc. at 633 nm) sequentially to avoid cross excitation and FRET. The 
micrographs were analyzed using a customized routine in Igor Pro 5.03v where threesholding, minimum 
particle area and ellipticity were used as tools to faithfully track particles and convert integrated intensity 
on the vesicle channel to vesicle diameter and intensity on the protein channel to protein density.[31]  
Results and discussion 
Design studies 
Based on this hypothesis we first analyzed the membrane binding of PYY3-36. Following this, we tested 
whether mutating the ‘address’ segment of PYY3-36 could help to increase or modulate binding affinity 
and receptor signaling. Here we studied PYY3-36 and introduced new analogs with a novel architecture 
by appending an additional amphipathic !-helix to the existing !-helix in PYY3-36, via the relatively 
rigid natural turn segment (Figure 1). 
Native human PYY3-36 displays high potency towards the Y2 receptor subtype but is only moderately 
selective as it also activates the Y1 and Y5 receptors.[32] Further N-terminal truncation to, for example, 
PYY13-36 (peptide 1, Table 1 and 2) reduces the affinity towards the anorectic Y2 receptor 
significantly.[33] Our strategy was to introduce a second amphipathic !-helix at the N-terminus of 
PYY13-36 which contains the natural turn motif, followed by the !-helix (‘address’) and the receptor 
binding pentapeptide (‘message’), This would provide a helix-turn-helix sequence (Figure 1). The new, 
appended !-helix had to be amphipathic and bind to the outer leaflet of the membrane. For this, we chose 
a de novo designed peptide sequence with a general heptad repeat structure (which previously has been 
used in artificial proteins)[34-36] as a general platform for further modifications. First, we studied which 
modifications were compatible with Y2 receptor binding, especially which could lead to a recovery of the 
high Y2 receptor affinity of PYY3-36, while improving the membrane binding. The first peptide in this 
series, peptide 2, had a significantly lower Y2 receptor affinity than native PYY3-36 and even the 
truncated peptide 1 (Table 1 and 2). This indicated that the particular structure incorporated to increase 
membrane affinity had to be balanced with the need for maintaining receptor docking. A modest 3-fold 
improvement in Y2 receptor affinity, relative to peptide 2, was obtained by inverting the chirality of the 
Pro in the linker region, peptide 6. Also substituting Tyr for Ala, peptide 5, and Glu for Ser, peptide 12, 
gave moderately improved Y2 receptor binding, in a manner which interestingly seemed to correlate with 
the pI. While other modifications, such as Leu to Phe or Trp mutations, or extension of the appended !-
helix lowered the Y2 receptor affinity. However, only minor changes in Y2 receptor affinity and potency 
were observed (peptides 3-14, Table 1 and 2). In contrast, extending the linker segment between the two 
!-helices with the GEDA sequence from PYY3-36 (peptide 15) improved both binding (7-fold) and 
activity (3-fold) at the Y2 receptor compared to peptide 2. Interestingly, the extended linker segment also 
resulted in a reduced Y1 and Y4 receptor binding affinity. 
To further improve the activity of the linear 2-helix analogs, the artificial N-terminal !-helix of peptide 
2 was exchanged by other heptad repeat sequences[37-39] (peptides 16-19). The de novo !-helix of 
peptides 16, 17 and 19 are more hydrophilic compared to the !-helices of peptides 2-15, and peptide 18 is 
more hydrophobic. In peptides 16 and 17 residues at position c and g of the heptad repeat segment were 
swapped (LKELERK in peptide 16 vs. LKKLERE in peptide 17). Peptides 16 and 17 both displayed a 
2-3 fold increased binding at the Y1 receptor, slightly less for peptide 16, and 10-fold increased binding 
to the Y2 and Y5 receptors compared to peptide 2 (Table 1). The signal transduction assay of peptide 16 
and 17 confirmed the receptor selectivity obtained from the binding experiments (Table 2). The more 
hydrophobic peptide 18 showed as low binding to all Y receptors and low activity as peptide 2. Altering 
the heptad repeat !-helix such that the positively charged Lys residues were clustered in the center of the 
heptad repeat (peptide 19) resulted in very high Y2 receptor affinity and potency but, unfortunately, only 
in minor decreases in binding affinity to the Y1 and Y5 receptor compared to PYY3-36 (Table 1 and 2). 
Interestingly, although peptide 19 had an Y1 receptor affinity similar to PYY3-36, the signal transduction 
assay showed a significantly lowered potency at the Y1 receptor, thus peptide 19 was a nanomolar Y2 
receptor agonist with improved Y2/Y1 receptor selectivity. However, as peptide 19 retained an 
unfavorably high Y5 potency, peptide 17 was chosen for further studies.  
To summarize our design studies, novel PYY3-36 analogs with high binding affinity and potency, in 
addition to good selectivity to the Y2 receptor were derived upon addition of a heptad repeat amphipathic 
!-helix to the truncated C-terminal !-helix of PYY. We focused on the natural pentapeptide SPEEL as the 
linker between the two !-helices. The distribution of charged or aromatic residues on the appended 
!-helix was crucial for achieving high affinity and selectivity. Generally, it seems that the more 
hydrophilic amphipathic heptad repeat sequences led to the highest Y2 receptor binding and potency. 
Interestingly, the most potent Y2 receptor agonists also activated the Y5 receptor indicating that ligand-
receptor interactions are very similar between the Y2 and Y5 receptors. Thus, radically redesigned PYY3-
36 variants with high potency and new properties were developed. Peptide 17 was chosen for further 
detailed biophysical studies because it presents the best compromise in terms of receptor affinity and 
receptor subtype selectivity. 
 
Structural studies 
In order to understand possible structural implications of the modifications several biophysical methods 
were used to characterize the peptides. CD spectra of PYY3-36 showed a degree of !-helicity of approx. 
28%. The novel Y2 agonists displayed !-helicities in solution of 25-52% (Table 2). CD indicated that the 
novel 2-helix PYY analogs possess medium to high !-helicity. A correlation between !-helicity and 
activity was, however, not observed, except as shown for peptide 14, where a low !-helicity was 
associated with an abolishment of activity. CD spectroscopy of both PYY3-36 and peptide 17, both in 
solution and in the association with lipid membranes (from standard rehydration of Folch bovine extracts) 
revealed a high content of !-helicity (Supporting Information). This is especially the case with 
dodecylphosphocholine (DPC) micelles, a detergent that contains the choline headgroup present in the 
outer leaflet of mammalian membranes.[40] 
Next we investigated the structure of peptide 17 in more detail by solution NMR. To characterize the 
membrane-bound state of peptide 17 we determined the structure of the peptide in presence of DPC 
micelles. The structure was determined based on upper-limits derived from nuclear Overhauser effects 
(NOEs) (for further details on the structure calculation see Table 3 as well as the Supporting Information). 
An expansion of the amide region displaying NOEs involving sequential amide protons as well as a single 
conformer of peptide 17 determined by NMR spectroscopy are depicted in Figure 2. The structure reveals 
the presence of two amphipathic !-helices encompassing residues 3-13 and 18-33. Both !-helices are well 
defined, and the individual superposition of backbone atoms of residues 3 to 13 or 18 to 33 yields RMSD 
values of 0.52 or 0.48 Å, respectively, and 1.92 Å when backbone atoms of both !-helices are 
superimposed. The C-terminal pentapeptide at the !-helix terminus of this 2-helix PYY variant, peptide 
17, is slightly less well defined than in PYY, as reflected in RMSDs of 1.1 vs. 0.76 Å, respectively, for 
backbone atoms of the C-terminal !-helix. However, the presence of both sequential as well as medium-
range NOEs at the end indicates that differences between PYY and peptide 17 are small (Supporting 
Information). Interestingly, the orientation of the !-helices with respect to each other is also defined, 
supported by a number of medium-range NOEs in the hinge region. 
The two !-helices are very well defined with apolar and polar residues clustered on opposite faces of 
the !-helices. In order to establish the topology of membrane-peptide association we measured distance-
dependent paramagnetic relaxation enhancement in the presence of the micelle-integrating spin label 
5-doxylstearate.[41] Attenuation of signals in the [15N,1H]-HSQC spectrum was measured after addition 
of the micelle-integrating spin-label. Strongest attenuation of signal, due to vicinities of the amide 
moieties to the membrane-water interfacial region, was observed for non-polar or aromatic residues, with 
the most notable exception being a strong reduction in signal intensity for Lys-14 (Supporting 
Information). The data reveal that the peptide associates with the micelle surface such that the apolar 
residues point towards the interface and the charged residues to the opposite (aqueous) side. 
 
Membrane binding 
PYY3-36 was N-terminally labeled with the fluorophor ATTO655 (for structure see Supporting 
Information) to provide peptide 20 for membrane affinity studies. A fluorescently labeled version of 
peptide 17 was constructed by incorporation of an N-terminal Cys, which was S-alkylated with maleimide 
functionalized ATTO655 to provide peptide 21 (Supporting Information). We have previously reported 
point mutations in peptides labelled with ATTO dyes, with supports that the membrane binding of 
amphipathic peptides is dominated by their sequence and not the dye.[42-43] The membrane binding of 
fluorescently labeled 20 (ATTO655-PYY3-36) and 21 (ATTO655-peptide 17) were also studied on 
fluorescently labeled single small unilamellar vesicles (Folch fractions from bovine brain, see methods) 
using confocal fluorescence microscopy (Figure 3).[44] Liposomes were immobilized by tethering on 
passivated glass surfaces through streptavidin-biotin linkages,[45] and were isolated at the single particle 
level simply by diluting their surface density several times below the optical resolution.[31,43-46] The 
exact diameter of each single vesicle (±5 nm) as well as the amount of labeled peptide bound on each 
liposome were calculated by integrating the respective fluorescence intensity signals and calibrating them 
using a procedure described in detail by Hatzakis et al.[43] (Figure 3). The ratio between the number of 
lipids and amount of bound peptides provided the density of peptide on the single vesicles.[43] 
Titration of peptide 21 at concentrations in the range from 10 nM to 200 nM to vesicles allowed 
recording the binding curve for the peptide-membrane interaction (Figure 3) and to extract the Kd from 
the fit as 4 nM. The binding of peptide 21 to the membrane reached a saturation density at "50 nM 
(Figure 3). PYY3-36, in contrast, did not reach saturation even at 600 nM, at which concentration the 
membranes began to deform. Consequently, the Kd for PYY3-36 towards the membrane could not be 
determined. Nevertheless, the fact that peptide 21 reached saturation at >12 fold lower concentration 
illustrates the prominent increase in membrane recruitment for peptide 21 (and 17) compared to PYY3-
36. In comparison, PYY1-36 has been reported to bind to DMPC and a 4:1 mixture of DMPC/DMPG 
vesicles in the micro molar range (determined by surface plasmon resonance experiments),[47] however, 
to our knowledge, no studies have been performed on PYY3-36. 
Discussion 
We have studied the ability of PYY3-36 to bind to membranes and designed a series of novel Y2 receptor 
ligands exploring the fact that the NPY family of peptides associates with the plasma membrane. We 
started from pharmacological screening and then proceeded to biophysical characterization of a single 
peptide. In order to increase membrane affinity of the peptides an amphipathic !-helix was appended at 
the N-terminal end of the original !-helix of PYY, i.e. the N-terminal part was exchanged for an artificial 
!-helix. The resulting analogs of PYY3-36 containing the more hydrophilic de novo designed helices lead 
to the most potent Y2 receptor ligands. The novel 2-helix PYY3-36 analogs displayed nanomolar Y2 
receptor potency, which in some cases was accompanied by an increase in Y2 receptor selectivity (Y2 
over Y1 or Y4). Interestingly, these analogs are similarly potent at the Y5 receptor. The data indicate that 
ligand-receptor interactions of Y2 and Y5 receptors are very similar, and supports previous work by 
Beck-Sickinger and co-workers using a complementary mutagenesis approach with NPY as the 
ligand.[48] 
In order to further understand the membrane binding properties of the redesigned peptides, peptide 17 
which displayed an interesting pharmacological profile was chosen for biophysical investigations. The 
NMR structure of peptide 17 in the presence of a membrane mimetic displayed two well-defined 
!-helices encompassing residues 3-13 and 18-33. Polar and apolar residues were clustered on different 
faces of the !-helices (Figure 2). The presence of a number of NOEs between residues of the N- and 
C-terminal helix proved that the two !-helices were not flexibly linked but rather adopted an L-shaped 
relative orientation. NMR showed only minor conformational differences in the C-terminal receptor-
binding pentapeptide between peptide 17 and PYY3-36, likely responsible for the similarity in the Y2 
receptor binding data. 
Previous studies have demonstrated that PYY1-36 and PYY3-36 share a common membrane-binding 
mode.[20-21] Moreover, the pharmacological assays revealed that some of the PYY3-36 analogs 
described here, which were designed to more tightly associate with the membrane, maintained high Y2 
receptor affinity. The novel nanoscale surface-based assay provides unique information about the 
membrane binding capacity of the peptide. Since the two !-helices in peptide 17 are not flexibly linked 
but rather form an L-shaped molecule, the architecture of the amphipathic nature of the peptide is well 
suited for binding to membranes. We speculate that these two features help in the recruitment to the 
membrane, and in the accumulation of the peptide in membrane compartments. In that respect it is of 
interest that it has been previously hypothesized that the amphipathic 8th helix of the rhodopsin-like 
family of GPCRs can act as a sensor for lipid composition or membrane curvature.[49] Moreover, the 
GPCRs may introduce lipid packing defects that can induce membrane bending,[43] resulting in 
recruitment of ligands like PYY towards the receptors.[50-51] In that context it is important to note that 
GPCRs are not uniformly distributed in the plasma membrane but are rather enriched in discrete areas of 
the plasma membrane such as lipid rafts that display distinct lipid and protein composition and membrane 
thickness.[52] Varying the membrane affinity may constitute a tool for creating peptides with selectivity 
for receptor populations in specific membrane environments that could affect the pharmacological profile 
of the peptides in a tissue-dependent manner. 
Association of peptides with membranes is not expected to influence Y receptor subtype selectivity as 
such. Improved Y receptor subtype selectivity thus is rather due to direct interactions with the receptor. 
Also, a peptide with improved membrane binding would still need to correctly dock into the receptor to 
exhibit the desired effect. Thus, the method for increasing membrane binding may have to be optimized 
for a particular peptide to not interfere with receptor docking. Although peptide 17 bound to model 
membranes with higher affinity compared to PYY3-36, this apparently was not directly translated into 
higher affinity at any of the other Y receptors under the conditions of the present study. It is likely that the 
addition of the heptad repeat sequences can affect receptor affinity negatively. Indeed, the first 2-helix 
variant, peptide 2, had a 65-fold reduced Y2 receptor affinity compared to PYY3-36. It is noteworthy that 
compared to peptide 2 the affinity of peptide 17 was increased for the Y1, Y2, and Y5 receptors (10-fold 
in case of the Y2 receptor). Thus, a new strategy for modulating and optimizing the properties of peptide 
hormones has been established. 
 
Conclusion 
In conclusion, we herein present a radical redesign of the pharmacologically important peptide hormone 
PYY3-36 to improve membrane binding. Appending an additional amphipathic helix to form a novel 
2-helix variant increased the membrane-binding affinity over the native PYY3-36. The new 2-helix 
variant retained a high binding affinity for the Y2 receptor as well as the activity. NMR studies revealed 
that when bound to DPC micelles both helices were fully formed and adopted a rigid L-shape. The 
membrane binding was related to the structure of the peptide, and in particular to the amphipathic nature 
of the two helices and their relative orientation. We have herein demonstrated that when properly 
choosing both the appended !-helix and the linker segment that connects the two helices both affinity and 
potency can be retained. These findings contribute to the hypothesis that membrane binding of 
amphipathic peptide hormones may play an important role in the binding to their membrane-bound 
receptors. Finally, the new concept demonstrated here for the redesign of the architecture of a 
biopharmaceutically important peptide can likely be extended to other important peptides for the 
development of potential drug candidates.  
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Figures and Tables 
 
Figure 1. The peptide design concept. The N-terminal half of PYY is replaced by an 
amphipathic !-helix. The native PYY !-helix is depicted in red and the appended !-helix in blue. 
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Figure 2. Left: Expansion of the amide proton region of the NOESY spectrum of peptide 17. 
Cross peaks corresponding to sequential contacts are annotated.   Right: Single conformer of 
peptide 17 as determined by solution NMR spectroscopy. Hydrophobic and polar side-chains 
are depicted in red and blue, respectively. The position of the micelle lipids is schematically 
shown. 
"  
 Figure 3. PYY3-36 and peptide 17 bind to brain lipid membranes. Single brain lipid 
vesicles of different size were immobilized on a glass surface using streptavidin-biotin 
linkage and imaged with confocal microscopy. Micrographs of vesicles (exc. 488 nm) (a 
and e) and labelled peptide (exc. 633 nm) respectively ATTO655-PYY3-36 (peptide 20) 
and ATTO655-peptide 17 (peptide 21) (b and f, respectively). The fluorescence intensities 
extracted from the images are used to quantitatively calculate liposome size and the 
density of bound peptide. Scale bar is 2 "m and applies to all micrographs. To guide the 
eye, data points have been simply connected by straight lines (e and f). Intensity profiles of 
cross section indicated by red line in e and f, illustrating the binding of peptide (grey) to 
vesicle membrane (red) by colocalized signal (g). Projection of native PYY3-36 helix and 
de novo !-helix in a helical wheel, demonstrating the increased amphipathicity (c). Binding 
of ATTO655-PYY3-36 (peptide 20) at different concentrations to vesicle membranes with a 
diameter of 75 (±5) nm (n=1009) (d). Saturation was not reached even at 600 nM, hence a 
Kd value for PYY3-36 could not be calculated. Binding curve of ATTO655-peptide 17 
(peptide 21) to vesicle membranes with a diameter of 75 (±5) nm (n=715) (h). The Kd of 
peptide 17 was calculated from the fit to be 4 nM. 
  
   
Table 1. Y receptor binding affinity of native PYY3-36 and the novel 2-helix PYY analogs. 
Peptide N-terminala 
Binding affinity assay IC50 [nM] 
Y1R Y2R Y4R Y5R 
PYY3-36 H-IKPEAPGEDASPEEL-X 32 ± 19 0.54 ± 0.15 255 ± 29 3.55 ± 1.86 
1 H-SPEEL-X 110 ± 59 6.63 ± 2.39 >1000 47.13  ± 14.09 
2 H-YEELLKKLEELLKKASPEEL-X 655 ± 234 35.97 ± 12.35 >1000 41.63  ± 15.37 
3 Ac-YEELLKKLEELLKKASPEEL-X >1000 67.00 ± 26.31 >1000 99.43 ± 28.51 
4 H-IKPEAPGYEELLKKLEELLKKASPEEL-X >1000 43.83 ± 14.16 >1000 57.43 ± 14.24 
5 H-AEELLKKLEELLKKASPEEL-X 661 ± 203 14.80 ± 5.54 >1000 39.87 ± 35.91 
6 H-YEELLKKLEELLKKASpEEL-X 324 ± 98 12.17 ± 1.21 >1000 7.74 ± 1.48 
7 H-YEELLKKLEELLKKASPeEL-X 793 ± 169 22.63 ± 9.32 >1000 22.83 ± 5.69 
8 H-YEELLKKLEELLKKASPEeL-X >1000 42.33 ± 15.14 >1000 49.37 ± 20.71 
9 H-YEELLKKLEELLKKASpeEL-X 528 ± 243 19.77 ± 4.13 >1000 13.84 ± 4.32 
10 H-YEEFFKKLEELFKKASPEEL-X >1000 84.80 ± 22.99 >1000 42.43 ± 10.28 
11 H-YEEWWKKLEELWKKASPEEL-X >1000 106.50 ± 18.62 >1000 39.27 ± 15.87 
12 H-YESLLKKLSELLKKASPEEL-X 400 ± 141 16.43 ± 4.69 >1000 34.67 ± 13.05 
13 H-YEELLKSLEELLKSASPEEL-X >1000 60.57 ± 28.51 >1000 150.57 ± 66.71 
14 H-YEELLKYLEELLKYASPEEL-X >1000 279.50 ± 14.85 >1000 387.00  ± 266.91 
15 H-YEELLKKLEELLKKAGEDASPEEL-X 179 ± 44 5.29 ± 2.20 >1000 7.10 ± 1.22 
16 H-YLERKLKELERKLKELSPEEL-X 260 ± 109 2.72 ± 1.90 >1000 9.36 ± 1.56 
17 H-YLERELKKLERELKKLSPEEL-X 154 ± 72 3.22 ± 1.55 >1000 10.45 ± 1.58 
18 H-YLKALKEALKALKEALKSPEEL-X 338 ± 110 27.00 ± 10.50 664 ± 276 35.30 ± 5.63 
19 H-NLEELKKKLEELKGSPEEL-X 36 ± 24 1.84 ± 0.62 532 ± 354 5.35 ± 0.84 
a) X = NRYYASLRHYLNLVTRQRY-NH2 (PYY18-36) 
   
Table 2. Y receptor potency of native PYY3-36 and the novel 2-helix PYY and their degree of !-helicity. 
Peptide N-terminala 
Signal transduction assay EC50 [nM] !-helicityb 
Y1R Y2R Y4R Y5R % 
PYY3-36 H-IKPEAPGEDASPEEL-X 14.00 ± 5.29 1.14 ± 0.27 >100 3.54 ± 0.06 26 
1 H-SPEEL-X >100 9.4 ± 1.4 >100 39.67 ± 8.39 32 
2 H-YEELLKKLEELLKKASPEEL-X >100 37 ± 5 >100 28.00 ± 1.73 45 
3 Ac-YEELLKKLEELLKKASPEEL-X >100 51 ± 7 >100 40.33 ± 3.79 40 
4 H-IKPEAPGYEELLKKLEELLKKASPEEL-X >100 >100 >100 57.67 ± 7.02 40 
5 H-AEELLKKLEELLKKASPEEL-X >100 55 ± 12 >100 25.00 ± 1.00 - 
6 H-YEELLKKLEELLKKASpEEL-X >100 26 ± 7 >100 9.47 ± 2.55 31 
7 H-YEELLKKLEELLKKASPeEL-X >100 74 ± 8 >100 21.33 ± 6.66 27 
8 H-YEELLKKLEELLKKASPEeL-X >100 89 ± 16 >100 32.67 ± 5.69 25 
9 H-YEELLKKLEELLKKASpeEL-X >100 39 ± 1 >100 9.14 ± 3.85 16 
10 H-YEEFFKKLEELFKKASPEEL-X >100 >100 >100 28.33 ± 3.06 42 
11 H-YEEWWKKLEELWKKASPEEL-X >100 >100 >100 32.33 ± 2.31 50 
12 H-YESLLKKLSELLKKASPEEL-X >100 59 ± 7 >100 35.00 ± 3.61 28 
13 H-YEELLKSLEELLKSASPEEL-X >100 32 ± 6 >100 40.00 ± 6.08 44 
14 H-YEELLKYLEELLKYASPEEL-X >100 >100 >100 68.00 ± 15.13 8 
15 H-YEELLKKLEELLKKAGEDASPEEL-X >100 13 ± 2 >100 4.24 ± 1.20 16 
16 H-YLERKLKELERKLKELSPEEL-X >100 19 ± 3 >100 15.33 ± 2.52 37 
17 H-YLERELKKLERELKKLSPEEL-X >100 15 ± 3 >100 11.33 ± 1.53 39 
18 H-YLKALKEALKALKEALKSPEEL-X >100 >100 >100 61.33 ± 23.18 - 
19 H-NLEELKKKLEELKGSPEEL-X >100 5.4 ± 0.5 >100 4.60 ± 0.53 26 
a) X = NRYYASLRHYLNLVTRQRY-NH2 (PYY18-36) 
b) Determined by CD spectroscopy 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Table 3. Structural statistics for the peptide 17. 
 NMR distance restraints:  
  Total NOE 429 
  Short-range, |i – j| # 1 304 
  Medium-range, 1 < |i – j| < 5 124 
  Long-range, |i – j| $ 5 1 
  Maximal distance restraint violation 0.25 Å 
 AMBER energies:  
  Total (mean and s.d. of 20 conformers) !1287 ± 66 kcal/mol 
  van der Waals !45 ± 13 kcal/mol 
 RMS deviations from idealized geometry:  
  Bond lengths 0.0259 ± 0.0011 Å 
  Bond angles 2.00 ± 0.04° 
 Ramachandran plot statistics:   
  Residues in most favored regions 78% 
  Residues in additionally allowed regions 20% 
  Residues in generously allowed regions 1% 
  Residues in disallowed regions 1% 
 RMS deviations from the mean coordinates:  
  N, C!, C’ of residues 3–13, 18-33  1.92 Å 
  N, C!, C’ of residues 3–13 0.52 Å 
  N, C!, C’ of residues 18–33 0.48 Å 
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